Can giritinib treatment prolong survival?

Giritinib treatment can prolong survival. This conclusion is mainly based on the following aspects of evidence:

1.Clinical trial data support: In clinical trials for patients with relapsed or refractory FLT3mutated AML, giritinib has shown significant efficacy. Compared with salvage chemotherapy, patients treated with giritinib had significantly longer survival. Specifically, the median overall survival in the geritinib group was 9.3 months, which was significantly higher than the 5.6 months in the chemotherapy group. This data provides direct evidence that giritinib treatment can prolong patient survival.

2.Improved complete response rate: In addition to prolonging survival, giritinib also improved the complete response rate of patients. In clinical trials, the proportion of patients in the giritinib group achieving complete remission was higher than that in the chemotherapy group. This means that more patients can have their conditions significantly controlled and improved after receiving giritinib treatment, thus helping to prolong survival.

3.Drug action mechanism: As a dual inhibitor of FLT3 and AXL, giritinib can precisely target the FLT3 kinase and inhibit the growth and spread of leukemia cells. This targeted therapeutic effect provides a pharmacological basis for prolonging patient survival.

4.Patient feedback and practical application effects: In practical applications, many patients reported that their disease was effectively controlled and their survival was prolonged after using giritinib. These real-life cases further confirm the efficacy of giritinib in prolonging survival.

At the same time, it is worth noting that although giritinib has shown significant efficacy in prolonging survival, some side effects and risks may also occur during treatment. Therefore, when using giritinib, patients should pay close attention to their own reactions and changes in condition, and promptly report any discomfort or abnormalities to their doctors.